Exposure-response analysis of tezepelumab in patients with severe asthma to guide phase 3 dose selection

N. Ly (Mountain View, United States of America), Y. Zheng (Mountain View, United States of America), J. Griffiths (Gaithersburg, United States of America), R. Van Der Merwe (Cambridge, United Kingdom), B. Agoram (Mountain View, United States of America), L. Roskos (Gaithersburg, United States of America)

Source: International Congress 2018 – Asthma management

Session: Asthma management
Session type: Poster Discussion
Number: 1688

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Ly (Mountain View, United States of America), Y. Zheng (Mountain View, United States of America), J. Griffiths (Gaithersburg, United States of America), R. Van Der Merwe (Cambridge, United Kingdom), B. Agoram (Mountain View, United States of America), L. Roskos (Gaithersburg, United States of America). Exposure-response analysis of tezepelumab in patients with severe asthma to guide phase 3 dose selection. 1688

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.